Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Inari Medical Inc (NQ: NARI )

49.75 +0.75 (+1.53%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Inari Medical Inc

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Analyst Expectations for Inari Medical's Future
Via Benzinga
3 Beaten-Down Growth Stocks That I'm Loading Up On in 2023
These stocks are all down by at least 42% from their all-time highs despite impressive performances from their underlying businesses. 
Via The Motley Fool
Inari Medical Announces First Patient Enrolled in the DEFIANCE Trial, Randomized Controlled Trial Evaluating Clinical Outcomes of the ClotTriever® System in Deep Vein Thrombosis
From Inari Medical, Inc.
Via GlobeNewswire
Inari Medical Announces Preliminary 2022 Revenue and 2023 Guidance
From Inari Medical, Inc.
Via GlobeNewswire
What 6 Analyst Ratings Have To Say About Inari Medical
Via Benzinga
Analyst Ratings for Inari Medical
Analysts have provided the following ratings for Inari Medical (NASDAQ:NARI) within the last quarter: 
Via Benzinga
Where Inari Medical Stands With Analysts
Analysts have provided the following ratings for Inari Medical (NASDAQ:NARI) within the last quarter: 
Via Benzinga
Inari Medical Q1 Earnings Beat Street View, Lifts FY22 Sales Outlook Above Consensus
Via Benzinga
3 Remarkable Growth Stocks That Could Climb 39% to 46%, According to Wall Street
These companies are reporting financial results that aren't being reflected in their stock market performances. 
Via The Motley Fool
Inari Medical to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Inari Medical, Inc.
Via GlobeNewswire
2 Top Growth Stocks Down 42.6% and 68.5% to Buy Before They Rebound in 2023
These relatively reliable healthcare businesses are performing much better than their beaten-down stock prices would suggest. 
Via The Motley Fool
Inari Medical to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
From Inari Medical, Inc.
Via GlobeNewswire
Inari Medical: Battling Blood Clots
Inari Medical is a small medical outfit whose stock has gone through the wringer for nearly a year — but the story remains terrific and the stock is starting to act better. Let's take a closer look. 
Via Talk Markets
Recap: Inari Medical Q4 Earnings
Inari Medical (NASDAQ:NARI) reported its Q4 earnings results on Wednesday, February 23, 2022 at 04:01 PM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
Inari Medical Reports Third Quarter 2022 Financial Results
From Inari Medical, Inc.
Via GlobeNewswire
Inari Medical Announces In-hospital and 30-day Outcomes from the Fully Enrolled CLOUT Registry and Results from Propensity-Score Matched Comparison of CLOUT vs. ATTRACT
From Inari Medical, Inc.
Via GlobeNewswire
Where Inari Medical Stands With Analysts
Over the past 3 months, 6 analysts have published their opinion on Inari Medical (NASDAQ:NARI) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
Inari Medical to Announce Third Quarter 2022 Financial Results
From Inari Medical, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2022
Upgrades 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2022
Upgrades 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 13, 2022
Upgrades See all analyst ratings upgrades. 
Via Benzinga
Morgan Stanley Maintains Overweight Rating for Inari Medical: Here's What You Need To Know
Morgan Stanley has decided to maintain its Overweight rating of Inari Medical (NASDAQ:NARI) and lower its price target from $108.00 to $93.00. Shares of Inari Medical are trading up 0.74% over the last... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 21, 2022
Upgrades 
Via Benzinga
Inari Medical's Return On Capital Employed Insights
Benzinga Pro data, Inari Medical (NASDAQ:NARI) reported Q1 sales of $86.75 million. Earnings fell to a loss of $3.13 million, resulting in a 382.66% decrease from last quarter. 
Via Benzinga
A Preview Of Inari Medical's Earnings
Inari Medical (NASDAQ:NARI) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that Inari... 
Via Benzinga
Inari Medical Reports Mixed Q4 Earnings, Guides FY22 Sales Above Consensus
Inari Medical Inc's (NASDAQ: NARI) Q4 revenue was $83.2 million, up 14% sequentially and 71% Y/Y, beating the consensus of $78.16 million. The sequential growth was... 
Via Benzinga
The Daily Biotech Pulse: Kodiak Sinks On Adverse Study Outcome, Marinus Flags Delay In Clinical Trial, Mainz Biomed Gains On Positive Regulatory Development
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase... 
Via Benzinga
A Preview Of Inari Medical's Earnings
Inari Medical (NASDAQ:NARI) is set to give its latest quarterly earnings report on Wednesday, 2022-02-23. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
Earnings Scheduled For February 23, 2022
Companies Reporting Before The Bell • Sapiens Intl Corp (NASDAQ:SPNS) is likely to report earnings for its fourth quarter. • Plymouth Industrial REIT (NYSE:PLYM)... 
Via Benzinga
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.